What is Zacks Research’s Estimate for IRWD Q2 Earnings?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Investment analysts at Zacks Research boosted their Q2 2026 earnings per share estimates for Ironwood Pharmaceuticals in a research report issued to clients and investors on Monday, December 1st. Zacks Research analyst Team now forecasts that the biotechnology company will post earnings per share of $0.09 for the quarter, up from their prior forecast of $0.08. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q4 2026 earnings at $0.16 EPS and FY2026 earnings at $0.39 EPS.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings results on Monday, November 10th. The biotechnology company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.09 by $0.15. The company had revenue of $122.06 million for the quarter, compared to analyst estimates of $74.22 million. Ironwood Pharmaceuticals had a net margin of 8.70% and a negative return on equity of 15.17%.

Several other research firms have also recently commented on IRWD. Wall Street Zen upgraded Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 9th. Weiss Ratings reissued a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a research note on Monday. Finally, Wells Fargo & Company raised their target price on shares of Ironwood Pharmaceuticals from $1.00 to $3.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 11th. One analyst has rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $5.34.

Ironwood Pharmaceuticals Stock Performance

NASDAQ IRWD opened at $3.48 on Thursday. The firm’s fifty day moving average is $2.30 and its two-hundred day moving average is $1.39. Ironwood Pharmaceuticals has a one year low of $0.53 and a one year high of $5.13. The firm has a market cap of $566.13 million, a PE ratio of 21.75 and a beta of 0.18.

Institutional Trading of Ironwood Pharmaceuticals

Large investors have recently bought and sold shares of the company. Bank of America Corp DE increased its holdings in Ironwood Pharmaceuticals by 248.3% during the 3rd quarter. Bank of America Corp DE now owns 11,695,544 shares of the biotechnology company’s stock valued at $15,321,000 after acquiring an additional 8,337,672 shares in the last quarter. Armistice Capital LLC grew its holdings in Ironwood Pharmaceuticals by 44.7% during the 1st quarter. Armistice Capital LLC now owns 13,700,000 shares of the biotechnology company’s stock valued at $20,139,000 after buying an additional 4,232,000 shares during the last quarter. Millennium Management LLC increased its position in Ironwood Pharmaceuticals by 186.6% during the first quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company’s stock worth $9,349,000 after buying an additional 4,140,439 shares in the last quarter. Acadian Asset Management LLC raised its holdings in shares of Ironwood Pharmaceuticals by 147.6% in the second quarter. Acadian Asset Management LLC now owns 6,549,687 shares of the biotechnology company’s stock worth $4,685,000 after acquiring an additional 3,904,498 shares during the last quarter. Finally, AQR Capital Management LLC raised its holdings in shares of Ironwood Pharmaceuticals by 144.3% in the second quarter. AQR Capital Management LLC now owns 6,165,637 shares of the biotechnology company’s stock worth $4,422,000 after acquiring an additional 3,641,762 shares during the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.